NASDAQ: $BIAF
Strengthening the Path Forward
BioAffinity Technologies, a company recognized for its innovative work in respiratory diagnostics, has officially announced the successful closing of a $4 million registered direct financing. This capital raise, facilitated by WallachBeth Capital, marks a significant milestone for the firm as it continues to advance its commercial and operational goals.
Details of the Financing
The transaction, which was executed at the market under Nasdaq rules, involves the sale of common stock and a concurrent private placement. This strategic move is designed to provide the company with the necessary resources to support its ongoing business objectives. Key aspects of the announcement include:
- Total Capital Raised: $4 million.
- Arrangement: The financing was managed by WallachBeth Capital.
- Structure: A combination of a registered direct offering of common stock and a concurrent private placement.
- Pricing: Executed at the market, adhering to all applicable Nasdaq regulations.
What This Means for the Future
By securing this $4 million influx of capital, BioAffinity Technologies is better positioned to execute its strategic roadmap. For investors and stakeholders, this closing represents a commitment to the company’s long-term vision within the biotechnology sector. As the firm moves forward, these funds are expected to play a crucial role in maintaining momentum for its diagnostic technology platform.
Source: Read More